Over the last decade, several monoclonal antibodies targeting immune checkpoint molecules, such as PD-1 and CTLA-4, have been developed and granted FDA approval for the treatment of various solid tumors by reversing T cell dysfunction, leading to tumor killing [141,142]. Here, CTLA4 is linked to neoplasm.